AU2001274940A1 - Fatty acid synthase inhibitors - Google Patents

Fatty acid synthase inhibitors

Info

Publication number
AU2001274940A1
AU2001274940A1 AU2001274940A AU7494001A AU2001274940A1 AU 2001274940 A1 AU2001274940 A1 AU 2001274940A1 AU 2001274940 A AU2001274940 A AU 2001274940A AU 7494001 A AU7494001 A AU 7494001A AU 2001274940 A1 AU2001274940 A1 AU 2001274940A1
Authority
AU
Australia
Prior art keywords
fatty acid
acid synthase
synthase inhibitors
inhibitors
fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001274940A
Inventor
Siegfried Benjamin Christensen
Robert A Daines
Martha S. Head
Jack Dale Leber
Mei Li
Joseph Weinstock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2001274940A1 publication Critical patent/AU2001274940A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AU2001274940A 2000-05-24 2001-05-24 Fatty acid synthase inhibitors Abandoned AU2001274940A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20691200P 2000-05-24 2000-05-24
US60206912 2000-05-24
PCT/US2001/016866 WO2001090099A1 (en) 2000-05-24 2001-05-24 Fatty acid synthase inhibitors

Publications (1)

Publication Number Publication Date
AU2001274940A1 true AU2001274940A1 (en) 2001-12-03

Family

ID=22768494

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001274940A Abandoned AU2001274940A1 (en) 2000-05-24 2001-05-24 Fatty acid synthase inhibitors

Country Status (5)

Country Link
US (1) US20030220392A1 (en)
EP (1) EP1299376A1 (en)
JP (1) JP2003534340A (en)
AU (1) AU2001274940A1 (en)
WO (1) WO2001090099A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014363A1 (en) * 1999-08-23 2001-03-01 Smithkline Beecham Corporation Fatty acid synthase inhibitors
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
EP2566853B1 (en) 2010-05-05 2017-01-25 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
CN102675211A (en) * 2011-03-17 2012-09-19 南京大学 Synthetization of secnidazole cinnamate derivative, and applications of secnidazole cinnamate derivative on antibacterial agent
PE20160122A1 (en) 2013-03-13 2016-02-12 Forma Therapeutics Inc NOBLE COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
CN113382633A (en) 2018-10-29 2021-09-10 福马治疗股份有限公司 Solid forms of (4- (2-fluoro-4- (1-methyl-1H-benzo [ d ] imidazol-5-yl) benzoyl) piperazin-1-yl) (1-hydroxycyclopropyl) methanone

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2816190A1 (en) * 1978-04-14 1979-10-25 Bayer Ag NEW BENZODIOXOL DERIVATIVES

Also Published As

Publication number Publication date
EP1299376A1 (en) 2003-04-09
WO2001090099A1 (en) 2001-11-29
JP2003534340A (en) 2003-11-18
US20030220392A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
AU2001258771A1 (en) -secretase inhibitors
AU2002219555A1 (en) VLA-4 Inhibitors
AU2001270200A1 (en) Fatty acid synthase inhibitors
AU2001278986A1 (en) 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors
AU2001236052A1 (en) Urease inhibitors
AU2001281059A1 (en) Fatty acid synthase inhibitors
AU2001280167A1 (en) Novel propenohydroxamic acid derivatives
AU2002222627A1 (en) Tak1 inhibitors
IL153230A0 (en) Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
IL148324A0 (en) Fatty acid synthase inhibitors
AU7961300A (en) Kainic acid neurocytotoxicity inhibitors
AU2001271531A1 (en) Fatty acid synthase inhibitors
AU2002224550A1 (en) Corrosion inhibitors
AU2002243439A1 (en) Fatty acid synthase inhibitors
AU2001274940A1 (en) Fatty acid synthase inhibitors
IL151250A0 (en) Difluorobutyric acid metalloprotease inhibitors
GB0030284D0 (en) Enzyme inhibitors
AU6925500A (en) Fatty acid synthase inhibitors
AU2001271718A1 (en) Fatty acid synthase inhibitors
AU6926500A (en) Fatty acid synthase inhibitors
AU2001291160A1 (en) Fatty acid synthase inhibitors
AU2001284705A1 (en) Fatty acid synthase inhibitors
AUPQ851000A0 (en) Rapid fatty acid delivery
AU2001268853A1 (en) Biocatalyst inhibitors
AU2001269121A1 (en) Substituted amidoalkyl-uracils as parp inhibitors